Associate Professor Michael Savona, MD
Dr. Michael Savona received his medical degree from Wake Forest University School of Medicine in Winston-Salem, North Carolina. He completed his residency as active duty with the United States Air Force at the University of California in San Francisco and Sacramento, California, and his fellowship in hematology and oncology at the University of Michigan in Ann Arbor. He later served as faculty at the San Antonio Military Medical Center in the United States Air Force, and is a veteran of Operation Enduring Freedom/Operation Iraqi Freedom. Dr. Savona is an Associate Professor of Medicine at Vanderbilt University School of Medicine and serves as Director of Hematology Research and the Hematology Early Therapy Program Vanderbilt‐Ingram Cancer Center. He previously served as the Director of Leukemia Research, and Senior Investigator, Drug Development, at Sarah Cannon Research Institute, where he built a world-renown hematology phase I program.
Dr. Savona is board certified in medical oncology and hematology, and is an elected fellow of the American College of Physicians. He is the founder and chairman of the MDS/MPN International Working Group, and the principal of the International Study of novel therapy for MDS/MPN: ABNL MARRO. Dr. Savona is a physician scientist and medical oncologist specializing in myeloid malignancies, and a leader in development of novel therapies for these diseases. His laboratory focuses on human cell biology with primary patient samples while examining novel compounds in the hopes of advancing them to the clinic.
Professor Greg Nowakowski, MD
Grzegorz (Greg) Nowakowski, M.D., is a consultant and a Professor of Medicine and Oncology, Division Head of Hematology at Mayo Clinic in Rochester, Minnesota, where he also serves as the Aggressive Lymphoma Program Director, Chairman of Education and Advanced Hematology Fellowship Program Director. He is a member of Mayo Clinic Cancer Center, and he also serves as an Associate Director of Epigenomic Program for Center of Individualized Medicine.
Dr. Nowakowski received his MD from the Medical University of Warsaw, Poland. He completed his internal medicine residency at Yale University Medical School – Norwalk Hospital, Norwalk, Connecticut and his fellowship in Hematology and Medical Oncology at Mayo Clinic, Rochester, Minnesota. Dr. Nowakowski joined the Mayo Clinic Lymphoma Group in 2006 as a Mayo Foundation Scholar. He is an alumnus of the American Society of Hematology (ASH) Clinical Research Training Institute and American Society of Clinical Oncology (ASCO) Leadership Development Program.
Dr. Nowakowski’s research focuses on the molecular classification and biology of lymphoproliferative disorders, new approaches to clinical trial design and novel therapies for lymphoma and hematological disorders. He is an investigator in the University of Iowa/Mayo Clinic Lymphoma Specialized Center of Research Excellence program, where he leads multiple projects on precision medicine and use of real-world data to support early drug development. Dr. Nowakowski has authored over 120 articles and numerous book chapters. Dr. Nowakowski serves as a principal investigator of multiple investigator-initiated and cooperative group clinical trials (ECOG, Alliance) and a member of ECOG Lymphoma Core Committee. Dr. Nowakowski also chairs the Lymphoma Committee and Hematological Malignancy Program in the Academic and Community Cancer Research United (ACCRU) network. He currently serves as a member of the ASH Committee on Scientific Affairs and ASH Taskforce on Molecular Hematology. He chairs the ASH Working Group on Clinical Trial Innovation. He also serves as a member of the American Society of Clinical Oncology (ASCO) Conquer Cancer Foundation Award Selection Committee and the ASCO Research Community Forum. Dr. Nowakowski is currently a Voting Member of the Oncology Drugs Advisory Committee (ODAC) to the Food and Drug Administration (FDA).
Professor Przemysław Juszczyński, MD, PhD
Professor Przemysław Juszczyński graduated from the Faculty of Medicine at the Medical University of Lodz in 2000. In 2002, he received PhD degree at the same University.
In 2001-2005 prof. Juszczyński was an Assistant at the Department of Hematology, Medical University of Lodz, and in 2003-2008 he worked as a Research Fellow at the Dana-Farber Cancer Institute in Boston, USA. Then, throughout 2008-2010, prof. Juszczyński held a position of the Instructor in Medicine at Harvard Medical School/Dana Farber Cancer Institute in Boston. Dr. Juszczyński is currently appointed as Professor at the Institute of Hematology an Transfusion Medicine in Warsaw. Since 2011, prof. Juszczyński also acts as Deputy Science Director at the same Institute.
Prof. Juszczyński received numerous awards and prizes for his scientific activities and achievements, including winning twice the Foundation for Polish Science Fellowships, ICRETT scholarship (International Union Against Cancer, Geneva, Switzerland) and Special Fellow award from the Leukemia and Lymphoma Society of America Career Development Program. In 2014 he was awarded by the jury of the “Polacy z Werwą” contest in the category “Medicine”. In 2018, he received the Polish Minister of Science Award for outstanding achievements.
Professor Juszczynski’s research interests are focused on the pathogenesis and immunopathogenesis of leukemias and lymphomas and the development of targeted therapies. Professor Juszczyński takes an active part as a Principal Investigator and Coordinator of numerous national and international research projects. His studies are published in prestigious scientific journals such as Blood, Clinical Cancer Research, Cancer Cell, PNAS and the British Journal of Haematology.
Professor Alwin Krämer, MD, PhD
Professor Alwin Kramer graduated medicine from University of Mainz in 1992, and throughout following years he has been training in oncology at University of Heidelberg, McArdle Laboratory for Cancer Research in Madison, USA and Danish Cancer Society in Copenhagen.
Starting from 2005 he is a full professor of medicine at Heidelberg University and since 2006 he is a Division Head of Molecular Hematology/Oncology Division of Deutsches Krebsforschungszentrum (German Cancer Research Center, DKFZ).
Professor Kramer received numerous awards for his activities, including Scientific Award from Medical Oncology Working Group of the German Cancer Society, Vincenz-Czerny Award (German Hematology/Oncology Association, DGHO), Heisenberg fellowship (German Research Foundation, DFG).
Areas of his research and scientific interest include carcinoma of unknown primary origin, acute myeloid leukemia, chromosome aberrations, and genomic instability.
Professor Cezary Szczylik, MD, PhD
Professor of medicine, oncologist, head of Department of Oncology, Centre of Postgraduate Medical Education and European Health Centre in Otwock. Founder and President of the Foundation of Experimental and Clinical Oncology, co-founder of Postgraduate School of Molecular Medicine. Member of the Polish Society of Oncology, co-author of the National Program for Fighting Cancer in Poland, member of the Program Council of the “Porozumienie bez Barier” Foundation and member of the Scientific Council of the Banking Foundation named after Leopold Kronenberg.
Professor Szczylik graduated medicine from Military Medical Academy in Łódź. He was a fellow of the American Leukemia Found in Temple University School of Medicine and Thomas Jefferson University. He was a long-term head of Department of Oncology and Laboratory of Molecular Oncology at the Military Institute of Medicine in Warsaw. In 1984, together with professor Wiesław Jędrzejczak, he performed the first allogeneic stem cell transplantation in Poland, and in 1985 – autologous stem cell transplantation. Currently, his main area of scientific interest is personalized and translational medicine, in particular molecular diagnostics and targeted therapy for kidney cancer.
Professor Szczylik is a primary investigator in clinical trials of all phases in oncology, co-author of several hundred scientific articles published, among others, in Science, New England Journal of Medicine and Lancet. Among many others distinctions, he received the Knight’s Cross of the Order of Polonia Restituta and the Golden Cross of Merit. For many years, he has been at the forefront of the most influential people of Polish medicine according to ‘Puls Medycyny’ magazine.